Olopatadine: all 36 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese SubjectsCompletedNCT02322216Phase 3Results posted
• Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in JapanCompletedNCT02251613Phase 4Results posted
• Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic ConjunctivitisCompletedNCT01743027Phase 3Results posted
• A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic ConjunctivitisCompletedNCT01732757Phase 4Results posted
• A Six-Week Safety Study of an Investigational Ophthalmic SolutionCompletedNCT01698814Phase 3Results posted
• Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis PatientsCompletedNCT01697969Phase 4Results posted
• Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) ModelCompletedNCT01479374Phase 3Results posted
• A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic ConjunctivitisCompletedNCT01470118Phase 4Results posted
• Assessment of Alcon's Ocular Image Quantification SystemCompletedNCT01282138Phase 4Results posted
• Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic ConjunctivitisCompletedNCT01159769Phase 4Results posted
• Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic ConjunctivitisCompletedNCT01119287Phase 4Results posted
• Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy SymptomsCompletedNCT01007253Phase 4Results posted
• Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor RhinitisCompletedNCT00979615Phase 4Results posted
• Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)CompletedNCT00818805Phase 4Results posted
• Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of AgeCompletedNCT00794144Phase 2Results posted
• Safety of PATANASE Nasal Spray in Patients With Perennial Allergic RhinitisCompletedNCT00789555Phase 4Results posted
• Olopatadine Eye Drops and Allergy Skin TestingCompletedNCT00775658Not applicableResults posted
• Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic RhinitisCompletedNCT00772304Phase 4Results posted
• Effect of Olopatadine on Allergic Tear MediatorsCompletedNCT00609128Not applicableResults posted
• Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old PatientsCompletedNCT00578929Phase 3Results posted
• Safety Study of Olopatadine Nasal SprayCompletedNCT00578331Phase 3Results posted
• A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic ConjunctivitisCompletedNCT05314621Phase 4
• A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic ConjunctivitisCompletedNCT05265910Phase 4
• Comparing Patient Satisfaction With Pataday or BepreveCompletedNCT01450176Not applicable
• Safety and Comfort of AL-4943A Ophthalmic SolutionCompletedNCT01326858Phase 1
• Patient Perception Study for AL-4943ACompletedNCT01294969Phase 4
• A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.TerminatedNCT01287338Phase 2
• A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic ConjunctivitisCompletedNCT01272089Phase 4
• Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric PatientsCompletedNCT01109485Phase 4
• An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to PlaceboWithdrawnNCT01076439Phase 4
• An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic ConjunctivitisCompletedNCT01037179Phase 3
• Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese SubjectsCompletedNCT00987272Phase 3
• A Comparison of Olopatadine and Fluticasone in Patients With Allergic ConjunctivitisCompletedNCT00655109Phase 4
• Comparison of CL Wear Between Two Allergy DropsWithdrawnNCT00489398Phase 4
• Mast-Cell Stabilizing Effects of OlopatadineCompletedNCT00389025Phase 4
• Olopatadine 0.2% for the Treatment of Allergic ConjunctivitisCompletedNCT00331500Phase 3

← Olopatadine overview